ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO023

Loop Diuretic Challenge to Predict the Need for Renal Replacement Therapy Among Patients with Stage III AKI

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials


  • Sakhuja, Ankit, Mayo Clinic, Rochester, Minnesota, United States
  • Barreto, Erin F., Mayo Clinic, Rochester, Minnesota, United States
  • Albright, Robert C., Mayo Clinic, Rochester, Minnesota, United States
  • Kashani, Kianoush, Mayo Clinic, Rochester, Minnesota, United States

A poor response to a high dose loop diuretic challenge (LDC) predicts the progression of stage I and II acute kidney injury (AKI). Performance of this diagnostic test in stage III AKI is unknown. The objective of this study was to determine if poor response to LDC among patients with stage III AKI predicted the need for renal replacement therapy within 24-hours (dialysis24h).


We included adults (≥18 years) admitted or transferred to medical or general surgical ICUs at Mayo Clinic, Rochester, MN between Jan 1, 2004, to Dec 31, 2016. Patients with stage III AKI were identified by an electronic surveillance tool using AKIN criteria. We then identified patients who received LDC, defined as at least 1mg/kg intravenous bolus dose of furosemide or equivalent intravenous bolus dose of bumetanide after the diagnosis of stage III AKI. We excluded patients with the end-stage renal disease, organ transplantation or who died within 24 hours of LDC. We modeled post-LDC urine output as a restricted cubic spline and compared the area under the curve (AUC) for urine output (mL) at 2h (UOP2h) and 6h (UOP6h) after LDC to predict dialysis24h.


We included 687 patients with stage III AKI who received LDC. The patients who received dialysis24h were younger (63.9 ± 14.5 years vs. 67.6 ± 15.6 years, p= 0.008), had lower Charlson comorbidity indices (4.9±2.4 vs. 5.8±2.7, p< 0.001) and higher SOFA scores on the day of LDC (10.4±3.9 vs. 8.2±3.4, p< 0.001). Both median total 2 hours (UOP2h) and 6 hours (UOP6h) urine output after LDC were lower in patients who needed dialysis24h (UOP2h 48ml vs. 138ml, p<.001; UOP6h 210ml vs. 616ml, p< 0.001) but UOP6h was better in predicting dialysis24h (Area under the curve 0.71 vs. 0.67, p= 0.02). The sensitivity and specificity of a UOP6h cutoff of ≤600ml to predict dialysis24h was 80.9% & 50.5% and for a cutoff of ≤300cc was 64.2% & 68.2%.


Among patients with AKI stage III the UOP6h after loop diuretic challenge had a modest discriminant capacity to identify dialysis initiation within the next 24 hours. Though its predictive power seems better in earlier stages of AKI, LDC may be a useful adjunct to assess dialysis needs in patients with advanced AKI.


  • Other NIH Support